We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+6.31%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$852M
AUM Growth
+$151M
Cap. Flow
+$154M
Cap. Flow %
18.03%
Top 10 Hldgs %
46.73%
Holding
164
New
33
Increased
26
Reduced
31
Closed
28

Top Buys

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$28.9M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$14.6M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$9.62M
4
FOLD
Amicus Therapeutics
FOLD
+$9.34M
5
PRTA icon
Prothena Corp
PRTA
+$7.38M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$18.6M
2
BIIB icon
Biogen
BIIB
+$9.88M
3
ITRN icon
Ituran Location and Control
ITRN
+$8.27M
4
ORBK
Orbotech Ltd
ORBK
+$6.41M
5
ZGNX
Zogenix, Inc.
ZGNX
+$5.08M

Sector Composition

Rank Sector Weight
1 Healthcare 58.93%
2 Technology 3.62%
3 Communication Services 2.25%
4 Financials 1.01%
5 Consumer Discretionary 0.94%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALDX icon
26
Aldeyra Therapeutics
ALDX
$92.9M
$7.1M 0.83%
1,044,131
– –
V icon
27
Visa
V
$684B
$6.89M 0.81%
60,401
+7,450
+14% +$823K
RETA
28
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$6.37M 0.75%
225,000
+20,000
+10% +$558K
GOOGL icon
29
Alphabet (Google) Class A
GOOGL
$4.36T
$6.08M 0.71%
115,340
– –
PVLA
30
Palvella Therapeutics
PVLA
$1.99B
$6.04M 0.71%
10,000
-2,500
-20% -$1.16M
META icon
31
Meta Platforms (Facebook)
META
$1.42T
$6.01M 0.71%
34,067
+1,900
+6% +$336K
NOMD icon
32
Nomad Foods
NOMD
$1.66B
$5.75M 0.67%
340,162
+173,500
+104% +$2.7M
KYNB
33
Kyntra Bio
KYNB
$27.2M
$5.68M 0.67%
4,791
-400
-8% -$502K
CBIO
34
Crescent Biopharma
CBIO
$537M
$5.46M 0.64%
+3,250
New +$4.3M
OBSV
35
DELISTED
ObsEva SA Ordinary Shares
OBSV
$5.35M 0.63%
547,697
+287,500
+110% +$2.92M
ASND icon
36
Ascendis Pharma A/S
ASND
$16B
$5.19M 0.61%
129,474
– –
ARRY
37
DELISTED
Array Biopharma Inc
ARRY
$5.18M 0.61%
405,000
– –
ONCE
38
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$5.14M 0.6%
+100,000
New +$7.18M
ACAD icon
39
Acadia Pharmaceuticals
ACAD
$4.43B
$5.12M 0.6%
+170,000
New +$5.44M
DCPH
40
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$5.01M 0.59%
224,154
+149,154
+199% +$2.92M
SAGE
41
DELISTED
Sage Therapeutics
SAGE
$4.94M 0.58%
30,000
+23,882
+390% +$2.32M
ADMS
42
DELISTED
Adamas Pharmaceuticals
ADMS
$4.76M 0.56%
140,500
+25,000
+22% +$698K
MLNX
43
DELISTED
Mellanox Technologies, Ltd.
MLNX
$4.75M 0.56%
+73,446
New +$3.88M
INCY icon
44
Incyte
INCY
$24.2B
$4.74M 0.56%
+50,000
New +$5.23M
INCY icon
45
PUT
Incyte
INCY
$24.2B
$4.74M 0.56%
+50,000
New +$5.23M
NERV icon
46
Minerva Neurosciences
NERV
$185M
$4.69M 0.55%
96,875
+18,750
+24% +$930K
STML
47
DELISTED
Stemline Therapeutics, Inc.
STML
$4.68M 0.55%
300,000
– –
WIX icon
48
WIX.com
WIX
$2.3B
$4.5M 0.53%
+78,180
New +$4.84M
DCOY
49
Decoy Therapeutics
DCOY
$2.19M
– –
0
– –
XLF icon
50
State Street Financial Select Sector SPDR ETF
XLF
$56.7B
$4.33M 0.51%
+155,000
New +$4.17M
1
2
3 4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q4 2017 Portfolio in Review

As of Q4 2017, Sphera Funds Management held 164 positions worth $852M, up 22% from $701M the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Sphera Funds Management deployed $154M of net new capital in Q4 2017, opening 33 new positions and adding to 26 existing holdings. Its largest new stake was Viatris: 756,449 shares worth $32M.

By sector, the portfolio is most concentrated in Healthcare at 59% of assets, down from 63% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Biogen, an estimated $9.88M trimmed.

  • Sphera Funds Management's largest Q4 2017 buy was Viatris: 756,449 shares worth $32M.
  • Sphera Funds Management added most to Vertex Pharmaceuticals in Q4 2017, an estimated $9.62M increase.
  • Sphera Funds Management's biggest Q4 2017 reduction was Biogen, cutting an estimated $9.88M.
  • Sphera Funds Management fully exited Gilead Sciences in Q4 2017, selling an estimated $18.6M.
  • Sphera Funds Management's ten largest holdings make up 47% of its $852M portfolio in Q4 2017.
  • Sphera Funds Management opened 33 new positions and closed 28 in Q4 2017.
  • Sphera Funds Management's portfolio value rose 22% quarter-over-quarter to $852M.

Based on Sphera Funds Management's 13F filing for Q4 2017, filed 12 Feb 2018.